ACTAZE Tablets 45 mg pioglitazone (as hydrochloride) 45 mg tablet blister pack Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

actaze tablets 45 mg pioglitazone (as hydrochloride) 45 mg tablet blister pack

arrow pharma pty ltd - pioglitazone hydrochloride, quantity: 49.6 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy;. as dual therapy to improve glycaemic control, in combination with metformin or sulfonylurea in combination with insulin; as triple therapy to improve glycaemic control, in combination with metformin and sulfonylurea.

ACTAZE Tablets 30 mg pioglitazone (as hydrochloride) 30 mg tablet blister pack Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

actaze tablets 30 mg pioglitazone (as hydrochloride) 30 mg tablet blister pack

arrow pharma pty ltd - pioglitazone hydrochloride, quantity: 33.07 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; carmellose calcium - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy;. as dual therapy to improve glycaemic control, in combination with metformin or sulfonylurea in combination with insulin; as triple therapy to improve glycaemic control, in combination with metformin and sulfonylurea.

ACTAZE Tablets 15 mg pioglitazone (as hydrochloride) 15 mg tablet blister pack Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

actaze tablets 15 mg pioglitazone (as hydrochloride) 15 mg tablet blister pack

arrow pharma pty ltd - pioglitazone hydrochloride, quantity: 16.53 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy;. as dual therapy to improve glycaemic control, in combination with metformin or sulfonylurea in combination with insulin; as triple therapy to improve glycaemic control, in combination with metformin and sulfonylurea.